Benefit was maintained across MZL subtypes and subgroups, including splenic MZL, with particularly favorable 24-month outcomes among patients achieving complete response. Safety signals aligned with ...
Over a median follow-up in responders of 18.0 months (range 15-21), the median duration of complete response was 18.0 months ...
Investors new to biotech and pharma stocks can get a quick overview of a company's pipeline health with phase success rates. A leading biotech trade group has broken down success rates by phase and ...
Bevacizumab, Irinotecan, or Topotecan Added to Temozolomide for Children With Relapsed and Refractory Neuroblastoma: Results of the ITCC-SIOPEN BEACON-Neuroblastoma Trial Patients with ...
Early GO decision reached ahead of Q2’26 guidance based on GO criteria of 20 confirmed responders achieved with less than 40 planned participants completing open-label Part A ...
Patient-reported outcomes: The anal cancer patient lived experience. This is an ASCO Meeting Abstract from the 2022 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a full text ...
The intention of this publication is to provide Member States with examples of the analysis phase to form the foundation of SAT-based training programmes. Although methods of analysis vary, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results